Eris Lifesciences Launches Generic Semaglutide ‘SUNDAE’ in India
Eris Lifesciences Limited (BSE: 540596; NSE: ERIS) announced the launch of its generic Semaglutide under the brand 'SUNDAE' in India on March 21, 2026. The company aims to increase accessibility to advanced diabetes care with the introduction of this GLP-1 receptor agonist.Semaglutide, a GLP-1 receptor agonist, is a transformative therapy for Type 2 diabetes and weight management. Eris is introducing SUNDAE in multi-dose vial formats starting at Rs 1,290 per month for the 2 mg/1.5 ml and 4 mg/3 ml variants. A pen-device version is planned for April, priced at MRP of INR 4,000, INR 4,200 and INR 4,500 per month for the strengths 2mg/1.5ml, 4mg/3ml and 8mg/3ml respectively.
“Semaglutide represents a breakthrough in the management of diabetes and metabolic disorders, with the potential to significantly improve patient outcomes,” the company stated. “With the launch of SUNDAE, we are fulfilling our responsibility to make such advanced therapies truly accessible and affordable to a much larger patient population.”
Eris Lifesciences, established in 2007, has an annual branded formulations revenue of INR 3,000+ Cr. The company’s portfolio spans specialties such as Diabetes, Cardiovascular, Dermatology, Nephrology, Neurology, Women’s Health, Oncology and Critical Care. Eris manufactures a wide range of prescription products across several dosage forms in its 6 manufacturing facilities, and markets these products across India through a network of ~5,000 stockists and 5,00,000+ retail pharmacies.
Revenue and operating profit have grown 2.6x in the last 5 years, with FY25 revenue of INR 2,894 Cr.
Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.